EMA Authorised: Zefylti (filgrastim) — CuraTeQ Biologics s.r.o

View source ↗

Summary

The European Medicines Agency authorised Zefylti (filgrastim) as a biosimilar for neutropenia, hematopoietic stem cell transplantation, and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation
• Neutropenia

Drugs mentioned

• Zefylti (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer. MAH: CuraTeQ Biologics s.r.o. Decision date: 26/09/2025